CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND LIVER DISEASES LEARN MORE RSV hMPV COVID-19 HCV HBV Enanta’s chemistry-driven approach and drug discovery capabilities are focused on small molecule drugs for the treatment of viral infections and liver diseases such as respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV). Learn more about our research. LATEST NEWS NOVEMBER 22, 2021 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with We... Read More 1 2 3 ABOUT RESEARCH NEWS CAREERS INVESTORS Copyright 2021 Enanta Pharmaceuticals, Inc Privacy Policy Twitter Policy Terms Of Use Powered By Q4 Inc. (opens in new window) Follow Us twitter LinkedIn